Epistemic AI
Epistemic AI provides AI-driven strategic intelligence for biopharma, integrating specialized AI agents and scientific expertise to deliver analyst-reviewed competitive landscapes, target product profiles, and conference intelligence. Their platform connects and structures evidence across regulatory, clinical, scientific, patent, commercial, and conference data to support key life-science decisions. Services are delivered as dashboards, reports, executive decks, and structured data, with scheduled updates and source traceability ensured.
Industries
Nr. of Employees
small (1-50)
Products
Technology platform organizing regulatory, clinical, scientific, patent, market, and conference data into an interconnected evidence graph for analytical workflows.
Platform integrating AI agents and scientist review for evidence gathering, normalization, and scientific analysis, with delivery as dashboards, reports, and structured data.
Technology platform organizing regulatory, clinical, scientific, patent, market, and conference data into an interconnected evidence graph for analytical workflows.
Platform integrating AI agents and scientist review for evidence gathering, normalization, and scientific analysis, with delivery as dashboards, reports, and structured data.
Services
Scientist-reviewed analysis of competitor assets, clinical programs, catalysts, evidence gaps, and portfolio implications for biopharma companies.
Production of structured, evidence-based product profiles benchmarked to clinical and commercial standards, supporting product positioning and differentiation.
Ongoing analysis and synthesis of conference data, evidence updates, and readiness assessments for strategic planning.
Scientist-reviewed analysis of competitor assets, clinical programs, catalysts, evidence gaps, and portfolio implications for biopharma companies.
Production of structured, evidence-based product profiles benchmarked to clinical and commercial standards, supporting product positioning and differentiation.
Ongoing analysis and synthesis of conference data, evidence updates, and readiness assessments for strategic planning.
Expertise Areas
- Biopharma strategic intelligence
- Portfolio management for pharmaceutical development
- Competitive intelligence in life sciences
- Clinical trial analysis
Key Technologies
- Knowledge graph technology
- Specialized AI agents
- Generative AI for biomedical data
- Data analytics platforms
Key People
Stefano Pacifico
CEO, Co-Founder, Board Member
Daphna Halpern
COO
Heather Bowling
VP of Scientific Development
Emily Koo
Principal Computational Biologist
Kenneth Ashworth
VP Data
Nadeem Ahmad
CFO
Stefano Pacifico
CEO, Co-Founder, Board Member
Daphna Halpern
COO
Heather Bowling
VP of Scientific Development
Emily Koo
Principal Computational Biologist
Kenneth Ashworth
VP Data
Nadeem Ahmad
CFO
News & Updates
A decade-long study, using AI and knowledge graph technology, reveals increasing influence of strategic decisions in clinical trial terminations.
Launch of a generative AI system designed for life-science professionals for enhanced biomedical information access.
Coverage of AI-powered biomedical knowledge platform launch at an industry conference.
A client selects the evidence platform to improve competitive intelligence and trend analysis.
Analysis shows late-stage (Phase 2/3) clinical trial termination rates doubled over a decade, with business and portfolio decisions now the most frequent cause.
ClearView Healthcare Partners makes a $4 million strategic investment to advance biomedical AI technology.
A decade-long study, using AI and knowledge graph technology, reveals increasing influence of strategic decisions in clinical trial terminations.
Launch of a generative AI system designed for life-science professionals for enhanced biomedical information access.
Coverage of AI-powered biomedical knowledge platform launch at an industry conference.
A client selects the evidence platform to improve competitive intelligence and trend analysis.
Analysis shows late-stage (Phase 2/3) clinical trial termination rates doubled over a decade, with business and portfolio decisions now the most frequent cause.
ClearView Healthcare Partners makes a $4 million strategic investment to advance biomedical AI technology.